Abbott (ABT) Q2 2024: Medical Devices Surge 12% as Margin Expansion Outpaces Peers
Abbott’s Q2 marked a decisive acceleration in medical device growth and gross margin recovery, outpacing sector peers and powering a guidance raise for the second consecutive quarter. Strategic bets in diabetes, structural heart, and emerging market biosimilars are translating into broad-based momentum, while disciplined capital allocation and productivity gains are driving operating leverage. With COVID testing headwinds now largely behind, Abbott’s diversified portfolio is positioned for sustained, above-market growth into 2025.
Summary
- Device-Driven Outperformance: Double-digit medical device growth and margin expansion reset Abbott’s top-line trajectory.
- Strategic Portfolio Activation: Biosimilars, leadless pacing, and OTC CGM launches broaden growth levers across key markets.
- Guidance Momentum: Raised outlook signals confidence in multi-segment execution and durable operating leverage.
Business Overview
Abbott is a diversified global healthcare company operating across four major segments: medical devices, diagnostics, established pharmaceuticals, and nutrition. It generates revenue through a mix of branded medical technologies (including diabetes care, cardiovascular, and neuromodulation devices), diagnostic systems (core laboratory and point-of-care), generic pharmaceuticals in emerging markets, and nutrition products for both adults and children. Medical devices and diagnostics are the largest and fastest-growing contributors, while nutrition and established pharma provide stable, recurring revenue streams.
Performance Analysis
Abbott delivered organic sales growth above 9% excluding COVID testing, led by a standout 12% increase in medical devices and high single-digit gains in both established pharmaceuticals and nutrition. Structural heart, electrophysiology, and diabetes care (anchored by Freestyle Libre) each posted double-digit growth, reflecting the payoff from a multi-year innovation pipeline and targeted commercial execution.
Gross margin expansion was a clear highlight, supported by lower commodity costs, favorable product mix, and ongoing supply chain productivity initiatives. Adjusted operating margins not only recovered to pre-pandemic levels but are now expanding ahead of sector averages. Foreign exchange remained a notable headwind, reducing reported sales growth by over 3%, yet operational momentum more than offset currency drag.
- Device Portfolio Scale-Up: Diabetes care revenue hit $1.6 billion, up 20%, with new OTC launches (Lingo, Libre Rio) expanding addressable markets.
- Structural Heart Acceleration: Broad-based growth across TriClip, NaviTor, and Amulet drove segment outperformance, with Amulet U.S. sales up 45%.
- Emerging Market Pharma Strength: Branded generics and early biosimilar deals are building a new growth pillar in underpenetrated geographies.
Abbott’s execution in high-growth device segments is now translating into sustained top-tier revenue and profit growth, with guidance raised for both sales and EPS for the second time this year.
Executive Commentary
"Our performance continues to be driven by broad-based growth across the portfolio, with growth this quarter led by double-digit growth in medical devices and high single-digit growth in established pharmaceuticals and nutrition."
Robert Ford, Chairman and Chief Executive Officer
"We're in a pretty unique position relative to some of our peers in terms of our margin profile that we're already back to pre-pandemic levels. ... We're focused on the things that we can control and execute on, and in particular, some of this great portfolio contribution from our sales top line performance, particularly in accretive businesses, is a contributor here and one that we anticipate will continue to expand here throughout the year."
Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer
Strategic Positioning
1. Diabetes and Consumer Health Platform Expansion
Freestyle Libre’s continued global adoption and the U.S. launch of Lingo and Libre Rio—OTC continuous glucose monitoring (CGM) products—signal Abbott’s ambition to tap both the core diabetes market and the broader wellness segment. Management projects a multi-billion dollar opportunity even at modest penetration, leveraging learnings from international OTC launches and a dedicated consumer-focused team.
2. Structural Heart and Electrophysiology Leadership
Abbott’s structural heart portfolio is seeing accelerated adoption across multiple new product launches (TriClip, NaviTor, Amulet), with share gains in both repair and replacement markets. Electrophysiology (EP) grew 17% in Q2, slightly below market growth but well above historical rates, with mapping and ablation consumables driving recurring revenue and the Volt PFA portfolio set to launch next year.
3. Emerging Market Biosimilars as a Growth Pillar
The established pharmaceuticals division is building a capital-efficient biosimilars business, leveraging Abbott’s distribution and regulatory relationships in emerging markets. Early licensing deals for oncology, women’s health, autoimmune, and GLP-1 biosimilars will begin launching in 2025, with larger opportunities ramping in 2026–2027. This strategy avoids margin dilution while expanding access and category growth.
4. Margin Expansion Through Productivity and Mix
Dedicated gross margin teams, lower input costs, and a shift toward higher-margin device and diagnostic products are driving operating leverage. Management expects these tailwinds to persist, supporting both near-term EPS growth and long-term reinvestment capacity.
5. Disciplined Capital Allocation and Portfolio Management
Abbott maintains a balanced approach to capital deployment—prioritizing internal growth investments, dividend growth, opportunistic buybacks, and selective M&A. With a robust pipeline and high-ROIC historical execution, the company is positioned to sustain above-market growth without relying on large-scale acquisitions.
Key Considerations
Abbott’s Q2 results reflect a portfolio firing on multiple cylinders, but investors should monitor both execution risks and evolving competitive landscapes.
Key Considerations:
- OTC CGM Market Development: Success of Lingo and Libre Rio in the U.S. depends on consumer education, behavior change, and direct-to-consumer marketing effectiveness.
- Structural Heart Share Gains: TriClip and Amulet’s rapid adoption are expanding Abbott’s footprint, but ongoing competitive pressure, especially in MitraClip, remains a watchpoint.
- Biosimilars Ramp: The emerging market biosimilar strategy is capital-light, but uptake and long-term sustainability will be tested as launches scale in 2025–2027.
- FX and Global Macro Sensitivity: Currency headwinds reduced reported growth by over 3% in Q2, and management expects continued FX pressure in Q3 and full year.
- Litigation and Regulatory Scrutiny: Ongoing preterm infant formula litigation is not material to revenue, but remains a background risk for the nutrition segment.
Risks
Key risks include intensifying competition in diabetes CGM, structural heart, and EP markets, as well as execution risk in scaling biosimilars across diverse emerging markets. Prolonged FX headwinds and potential regulatory actions, particularly in nutrition and device approvals, could impact growth and margin targets. While management downplays the impact of ongoing litigation, adverse outcomes could create reputational or operational friction.
Forward Outlook
For Q3 2024, Abbott guided to:
- Adjusted EPS of $1.18 to $1.22
- Organic sales growth excluding COVID testing in the high single to low double digits
For full-year 2024, management raised guidance:
- Organic sales growth (ex-COVID) of 9.5% to 10%
- Adjusted EPS of $4.61 to $4.71
Management highlighted several factors that will shape the second half:
- Continued device and diagnostics momentum, with new product launches fueling growth
- Margin expansion from productivity, mix, and input cost tailwinds
Takeaways
Abbott’s Q2 results validate its multi-segment innovation strategy and margin recovery, with device-led growth and biosimilar expansion setting the stage for durable outperformance into 2025.
- Device and Diagnostic Outperformance: Sustained double-digit growth in high-value segments is now driving both top-line and operating leverage, with new launches (OTC CGM, TriClip, Amulet) broadening the opportunity set.
- Portfolio Activation and Capital Discipline: Biosimilars, emerging market pharma, and targeted M&A provide additional growth levers without margin dilution, while balanced capital allocation supports both reinvestment and shareholder returns.
- Watch for Execution on New Platforms: The success of OTC CGM and biosimilar launches will be pivotal for sustaining above-market growth, with competitive intensity and FX volatility as ongoing risks.
Conclusion
Abbott’s Q2 demonstrates a portfolio in full stride, with medical device momentum, margin expansion, and new growth pillars offsetting currency and litigation overhangs. With guidance raised and innovation levers activating, the company is positioned for continued sector leadership into 2025.
Industry Read-Through
Abbott’s broad-based device and diagnostic acceleration signals robust procedure volumes and innovation-driven share gains across medtech. The successful launch of OTC CGM products highlights growing consumerization in healthcare, with implications for both diabetes and broader wellness markets. Emerging market biosimilar expansion points to untapped opportunity for capital-light growth models in branded generics and specialty pharma. Margin recovery and productivity focus are likely to remain central themes for diversified healthcare peers as COVID headwinds recede and new product cycles accelerate.